Ionis Pharmaceuticals (IONS) Aktievy
Ionis Pharmaceuticals, Inc. är ett bioteknikföretag i kommersiell fas som tillhandahåller RNA-riktade läkemedel i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 6/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 3/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för IONS från våra riskkontroller.
IONS Community Fair Values
Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ionis Pharmaceuticals, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$55.87 |
| 52 veckors högsta | US$86.74 |
| 52 veckors lägsta | US$40.03 |
| Beta | 0.37 |
| 1 månads förändring | -26.99% |
| 3 månaders förändring | -23.75% |
| 1 års förändring | 32.25% |
| 3 års förändring | 40.41% |
| 5 års förändring | 50.43% |
| Förändring sedan börsintroduktionen | 458.70% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jul 23
IONS: Tryngolza Approval And Rare Disease Pipeline Will Reshape 2026 Risk Reward Profile
Ionis Pharmaceuticals' fair value estimate has been reset from $104.86 to $92.00, as analysts incorporate the Phase 3 eplontersen cardiomyopathy miss, related trims to revenue growth and profit margin assumptions, and a higher projected future P/E. These factors are all reflected in a wave of reduced price targets across the Street.Seeking Alpha • Jul 16
Ionis Pharmaceuticals: The Heartbreak Is Priced In
Summary The ATTR-CM and tominersen setbacks drove an excessive selloff without impairing Ionis’s wholly owned core assets. Tryngolza is the main value driver, supported by strong triglyceride and pancreatitis data and a large sHTG market. Dawnzera's upcoming pipeline catalysts and $1.9B of liquidity support growth and a credible path to 2028 breakeven. Despite reimbursement, competition, and execution risks, Ionis’s ~$9B valuation offers attractive upside, supporting a speculative BUY. Read the full article on Seeking AlphaRecent updates
Uppdatering av berättelse • Jul 23
IONS: Tryngolza Approval And Rare Disease Pipeline Will Reshape 2026 Risk Reward Profile
Ionis Pharmaceuticals' fair value estimate has been reset from $104.86 to $92.00, as analysts incorporate the Phase 3 eplontersen cardiomyopathy miss, related trims to revenue growth and profit margin assumptions, and a higher projected future P/E. These factors are all reflected in a wave of reduced price targets across the Street.Seeking Alpha • Jul 16
Ionis Pharmaceuticals: The Heartbreak Is Priced In
Summary The ATTR-CM and tominersen setbacks drove an excessive selloff without impairing Ionis’s wholly owned core assets. Tryngolza is the main value driver, supported by strong triglyceride and pancreatitis data and a large sHTG market. Dawnzera's upcoming pipeline catalysts and $1.9B of liquidity support growth and a credible path to 2028 breakeven. Despite reimbursement, competition, and execution risks, Ionis’s ~$9B valuation offers attractive upside, supporting a speculative BUY. Read the full article on Seeking AlphaUppdatering av berättelse • Jul 09
IONS: Severe Triglyceride Label Win Will Reshape 2026 Risk Reward Profile
Analysts have raised the Ionis Pharmaceuticals fair value estimate by about $3.94 to $104.86, citing updated price targets following the FDA approval of Tryngolza, as well as increased confidence in the company’s proprietary and partnered pipeline. Analyst Commentary Recent research on Ionis Pharmaceuticals clusters around the FDA approval of Tryngolza and its implications for valuation, execution risk and long term growth potential across the company’s proprietary and partnered pipeline.
Uppdatering av berättelse • Jun 25
IONS: FDA Approvals And 2026 Readouts Will Test Balanced Expectations
The analyst price target for Ionis Pharmaceuticals has been raised from $62.78 to $79.71, with analysts citing the FDA approval of Tryngolza and updated assumptions for revenue growth, profit margin, and future P/E as key drivers of the change. Analyst Commentary Recent Street research on Ionis Pharmaceuticals centers on the FDA approval of Tryngolza and how this new product feeds into long term revenue, margin, and P/E assumptions.Analysartikel • Jun 22
Ionis Pharmaceuticals (IONS) Stock Could Be 26.6% Undervalued After New Olezarsen Data
Ionis Pharmaceuticals (IONS) recently shared new long-term data on its RNA therapy olezarsen for severe hypertriglyceridemia, highlighting sustained effects on liver fat and a favorable safety profile in an ongoing extension study. See our latest analysis for Ionis Pharmaceuticals. Ionis Pharmaceuticals’ share price is US$74.12, with short term moves roughly flat as the 7 day share price return of 1.15% and 30 day share price return, down 1.91%, contrast with a much stronger 1 year total...Uppdatering av berättelse • Jun 11
IONS: Priority Review In Severe Triglycerides Will Drive 2026 Risk Reward Repricing
Analysts have lifted their average price target on Ionis Pharmaceuticals toward $115, reflecting renewed focus on the $3.5b-plus Tryngloza opportunity in severe hypertriglyceridemia and upcoming partnered Phase 3 readouts in 2026, while leaving the modeled fair value at about $100.92 as the discount rate and margin assumptions are fine tuned. Analyst Commentary Street research around Ionis Pharmaceuticals has centered on how much value to ascribe to Tryngloza and the broader pipeline, with recent work fine tuning price targets and risk assumptions rather than radically changing the fundamental narrative.Uppdatering av berättelse • May 28
IONS: Priority Review In Severe Triglycerides Will Reshape 2026 Risk Reward Profile
Ionis Pharmaceuticals' fair value estimate has moved from $96.73 to $100.92 as analysts factor in higher assumed revenue growth, a stronger profit margin profile, and a lower future P/E multiple, supported by a wave of higher price targets and fresh Buy initiations that highlight the potential of Tryngloza and upcoming partnered Phase 3 readouts. Analyst Commentary Recent Street research around Ionis Pharmaceuticals has been active, with multiple firms adjusting price targets and launching new coverage.Analysartikel • May 11
Need To Know: Analysts Are Much More Bullish On Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Revenues
Shareholders in Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) may be thrilled to learn that the analysts have just...
Uppdatering av berättelse • May 02
IONS: Priority FDA Reviews In 2026 Will Support Stronger Earnings Power
Analysts have nudged the Ionis Pharmaceuticals fair value estimate higher to $130 from $120, citing a series of price target increases across the Street and updated assumptions around growth, profitability, and future P/E levels. Analyst Commentary Recent Street research around Ionis Pharmaceuticals has leaned constructive, with a cluster of bullish analysts lifting price targets and reinforcing a positive view on execution and long term growth potential, even as one firm trimmed its target.Analysartikel • May 01
Earnings Beat: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) just released its first-quarter report and things are looking bullish. The...Uppdatering av berättelse • Apr 18
IONS: Priority Review For Severe Triglycerides Will Reframe 2026 Risk Reward Profile
Analysts have raised their fair value estimate for Ionis Pharmaceuticals by about $3 to $96.73, citing updated assumptions for higher revenue growth, a wider profit margin, and a lower future P/E multiple, along with a series of recent price target increases and positive ratings resets from major firms. Analyst Commentary Recent research updates on Ionis Pharmaceuticals have leaned constructive, with several firms lifting price targets and reiterating positive ratings following the latest quarterly results and pipeline updates.Uppdatering av berättelse • Apr 04
IONS: Priority FDA Reviews In 2026 Will Support Stronger Profitability Profile
Analysts have lifted the Ionis Pharmaceuticals fair value estimate by $3.24 to $120.00, as they factor in updated assumptions around revenue growth, profit margins, and future P/E multiples following recent price target increases across the Street. Analyst Commentary Bullish analysts have been lifting Ionis Pharmaceuticals price targets across several research updates, which feeds directly into the higher fair value estimate.Uppdatering av berättelse • Mar 20
IONS: Priority Review For Severe Triglycerides Will Shape 2026 Outlook
Ionis Pharmaceuticals' updated analyst price target moves higher to $93.90 from $90.67. Analysts point to recent target hikes, Q4 results commentary and upcoming 2026 catalysts as key supports for this shift.Uppdatering av berättelse • Mar 06
IONS: 2026 Regulatory Event Risk Will Test Elevated Expectations
Ionis Pharmaceuticals' fair value estimate has been raised from $43.00 to about $62.78 as analysts factor in higher long term revenue growth assumptions, updated margin expectations, and recent price target increases following Q4 results, olezarsen progress, and a busy 2026 catalyst calendar. Analyst Commentary Recent Street research on Ionis Pharmaceuticals points to a more constructive stance on the story overall, but there are still threads of caution that matter if you are thinking about risk, valuation, and execution over the next couple of years.Uppdatering av berättelse • Feb 19
IONS: Late-Stage RNA Programs Will Support Stronger Future Profitability Profile
Analysts have lifted their price target on Ionis Pharmaceuticals by $10, citing updated expectations around revenue growth, profit margins and a lower future P/E assumption, as reflected in recent research from firms covering the stock. Analyst Commentary Recent Street research points to a generally constructive tone on Ionis Pharmaceuticals, with bullish analysts highlighting both valuation and execution angles in their updated work.Uppdatering av berättelse • Feb 05
IONS: Triglyceride Market Shift And SHTG Launch Progress Will Shape Outlook
Analysts nudged their fair value target for Ionis Pharmaceuticals slightly higher to about US$90.67 from roughly US$90.63, citing updated assumptions around discount rates, revenue growth, profit margins and a higher future P/E, along with recent Street research that highlights evolving expectations for the triglyceride lowering market where Ionis and Arrowhead both participate. Analyst Commentary Bullish Takeaways Bullish analysts view the refreshed fair value near US$90.67 as consistent with a company that could justify a higher future P/E, reflecting confidence in execution rather than only near term trading sentiment.Uppdatering av berättelse • Jan 22
IONS: Upcoming SHTG Data And Launch Execution Will Support Bullish Thesis
Analysts have lifted their fair value estimate for Ionis Pharmaceuticals to about US$90.63 from roughly US$89.40, citing updated models that reflect recent Q3 performance, higher assumed revenue growth and profit margins, as well as a lower future P/E. This comes alongside Street price target increases to US$94 and US$99 following Tryngolza driven strength and expectations around upcoming SHTG data.Uppdatering av berättelse • Jan 08
IONS: Late-Stage Data And New Launches Will Shape Balanced Risk Profile
Analysts nudged their fair value estimate for Ionis Pharmaceuticals higher from about $85.95 to roughly $89.40. They pointed to updated models that reflect recent price target increases, added expectations for Tryngolza in FCS and severe hypertriglyceridemia, and revised long term margin and P/E assumptions.Uppdatering av berättelse • Dec 24
IONS: Late-Stage RNA Pipeline Will Drive Stronger Profitability Outlook
Analysts have raised their fair value estimate for Ionis Pharmaceuticals from approximately $96 to about $117 per share, citing strong Q3 outperformance led by Tryngolza, expanded peak sales assumptions for key lipid programs, and growing confidence in the late-stage pipeline and path to profitability. Analyst Commentary Bullish analysts are increasingly constructive on Ionis Pharmaceuticals following a series of positive catalysts, including strong Q3 performance from Tryngolza, encouraging late-stage data, and visible progress toward breakeven and long term profitability.Uppdatering av berättelse • Dec 10
IONS: Late-Stage Data And Multiple Launches Will Shape Balanced Long-Term Outlook
Analysts have modestly raised their fair value estimate for Ionis Pharmaceuticals to approximately $86 per share. This reflects higher peak sales assumptions for Tryngolza and other late stage programs, a slightly richer pricing outlook in severe hypertriglyceridemia, and growing confidence in the company reaching multi billion dollar revenue and profitability in the early 2030s.Uppdatering av berättelse • Nov 26
IONS: Upcoming Late-Stage Data and Recent Regulatory Progress Will Shape Balanced Outlook
Ionis Pharmaceuticals’ analyst price target has been raised from approximately $82 to $85 per share. This reflects analyst optimism following strong Phase 3 trial results, upward sales guidance, and an improved clinical and commercial outlook across multiple pipeline programs.Uppdatering av berättelse • Nov 05
IONS: Continued Clinical Success Will Drive Meaningful Upside After Recent Regulatory Wins
The consensus analyst price target for Ionis Pharmaceuticals has increased significantly, rising from approximately $77 to over $82. Analysts cite robust clinical trial results, new product milestones, and a strengthened commercial outlook as key drivers behind their upward revisions.Analysartikel • Nov 01
Earnings Update: Here's Why Analysts Just Lifted Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target To US$81.91
Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) defied analyst predictions to release its third-quarter results, which were...Uppdatering av berättelse • Oct 22
Analyst Commentary Highlights Ionis Pharmaceuticals’ Upward Price Target and Valuation Amid Key Clinical Wins
Ionis Pharmaceuticals’ analyst price target has been raised from approximately $73 to $77. Analysts cite stronger-than-expected clinical and commercial progress across key late-stage programs, as well as expanded opportunities in rare disease markets.Uppdatering av berättelse • Oct 08
Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach
Ionis Pharmaceuticals’ analyst price target has been raised from approximately $69.48 to $73.03, as analysts cite strong Phase 3 results across multiple programs and expanded opportunities in ultra-rare indications, which support increased sales and profit expectations. Analyst Commentary Recent analyst updates on Ionis Pharmaceuticals reveal a nuanced outlook as the company benefits from significant clinical milestones and expanding commercial prospects, but also faces some areas of uncertainty.Uppdatering av berättelse • Sep 23
Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach
Analysts increased their price targets for Ionis Pharmaceuticals following "groundbreaking" Phase 3 data for olezarsen, blockbuster expectations, and a major regulatory win for Dawnzera, resulting in a modest consensus target rise from $68.35 to $69.48. Analyst Commentary Bullish analysts significantly raised price targets after Phase 3 trial data for olezarsen/Tryngolza in severe hypertriglyceridemia showed "groundbreaking" or "highly statistically significant" triglyceride reductions and, notably, the first proven benefit in reducing acute pancreatitis.Analysartikel • Sep 03
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 34% Share Price Surge Not Quite Adding Up
Despite an already strong run, Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) shares have been powering on, with a gain of...Uppdatering av berättelse • Aug 27
Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach
Ionis Pharmaceuticals’ consensus price target edged up to $59.19 as analysts cited favorable FDA approval and label for Dawnzera in hereditary angioedema, strong initial launches, and growing pipeline confidence as key drivers, outweighing modest concerns on Wainua revenues. Analyst Commentary FDA approval of Dawnzera with a favorable, broad label (including both every four and eight week dosing) and absence of major safety warnings, positioning it competitively against Takhzyro and Andembry in hereditary angioedema.Analysartikel • Aug 01
Analysts Just Published A Bright New Outlook For Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS)
Celebrations may be in order for Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) shareholders, with the analysts delivering...Analysartikel • Jul 30
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Aktieägarnas avkastning
| IONS | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | 2.7% | -0.5% | -2.0% |
| 1Y | 32.3% | 29.7% | 15.1% |
Avkastning vs industri: IONS översteg US Biotechs branschen som gav 29.7 % under det senaste året.
Avkastning vs Marknaden: IONS översteg US marknaden som gav 15.1 % under det senaste året.
Prisvolatilitet
| IONS volatility | |
|---|---|
| IONS Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: IONS har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: IONS s veckovolatilitet ( 8% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1989 | 1,402 | Brett Monia | www.ionis.com |
Ionis Pharmaceuticals, Inc. är ett bioteknikföretag i kommersiell fas som tillhandahåller RNA-riktade läkemedel i USA. Företaget erbjuder TRYNGOLZA för att minska triglyceridnivåerna hos vuxna med familjärt kylomikronemisyndrom (FCS) och akut pankreatit, DAWNZERA för profylax för att förhindra attacker av ärftligt angioödem hos vuxna, WAINUA för behandling av polyneuropati vid ärftlig transtyretinmedierad amyloidos (ATTRv-PN) hos vuxna samt SPINRAZA för barn och vuxna med spinal muskelatrofi (SMA). Företaget tillhandahåller också QALSODY för behandling av amyotrofisk lateralskleros (ALS), TEGSEDI för behandling av ATTRv-PN hos vuxna samt WAYLIVRA för behandling av FCS och familjär partiell lipodystrofi.
Ionis Pharmaceuticals, Inc. Sammanfattning av grunderna
| IONS grundläggande statistik | |
|---|---|
| Börsvärde | US$9.23b |
| Vinst(TTM) | -US$326.98m |
| Intäkter(TTM) | US$1.06b |
8.7x
P/S-förhållande-28.2x
P/E-förhållandeÄr IONS övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| IONS resultaträkning (TTM) | |
|---|---|
| Intäkter | US$1.06b |
| Kostnad för intäkter | US$942.46m |
| Bruttovinst | US$115.73m |
| Övriga kostnader | US$442.71m |
| Intäkter | -US$326.98m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
Jul 29, 2026
| Vinst per aktie (EPS) | -1.98 |
| Bruttomarginal | 10.94% |
| Nettovinstmarginal | -30.90% |
| Skuld/egenkapitalförhållande | 478.3% |
Hur har IONS utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/24 19:12 |
| Aktiekurs vid dagens slut | 2026/07/23 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Ionis Pharmaceuticals, Inc. bevakas av 43 analytiker. 21 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| James Birchenough | Barclays |
| Eliana Merle | Barclays |
| Huidong Wang | Barclays |